| Dose level . | Dose of drug: SGN-2FF . | Dose of drug: Pembrolizumab . | Number enrolled . | Number evaluable for toxicity . |
|---|---|---|---|---|
| 1 | 2 g QD | 200 mg every 21 days | 4 | 4 |
| 2 | 5 g QD | 200 mg every 21 days | 3 | 3 |
| Dose level . | Dose of drug: SGN-2FF . | Dose of drug: Pembrolizumab . | Number enrolled . | Number evaluable for toxicity . |
|---|---|---|---|---|
| 1 | 2 g QD | 200 mg every 21 days | 4 | 4 |
| 2 | 5 g QD | 200 mg every 21 days | 3 | 3 |
| Dose level . | Dose of drug: SGN-2FF . | Dose of drug: Pembrolizumab . | Number enrolled . | Number evaluable for toxicity . |
|---|---|---|---|---|
| 1 | 2 g QD | 200 mg every 21 days | 4 | 4 |
| 2 | 5 g QD | 200 mg every 21 days | 3 | 3 |
| Dose level . | Dose of drug: SGN-2FF . | Dose of drug: Pembrolizumab . | Number enrolled . | Number evaluable for toxicity . |
|---|---|---|---|---|
| 1 | 2 g QD | 200 mg every 21 days | 4 | 4 |
| 2 | 5 g QD | 200 mg every 21 days | 3 | 3 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
